sndz This could be big !

[stockguy4]

Sunridge International Inc. (SNDZ)

 
OVER 67 MILLION people suffer from glaucoma worldwide.  Over 63,000 new cases are diagnosed each year.  If left untreated, glaucoma leads to blindness.

The best therapy is to reduce the fluid pressure to arrest damage to the optic nerve.

Current drug treatments come with heft side effects, low compliance (patients not taking the drugs as prescribed) and low success among certain populations.

-  People with glaucoma need a non-invasive and effective adjunct treatment.

-  Health care providers need improved efficiency and more effective treatments.

Ophthalmic International has developed and patented a procedure to treat glaucoma.  It's called PNT.

PNT is a non-invasive procedure that reduces and stabilizes fluid pressure in the eye - a simple 2-minute treatment at the doctor's office every 3-4 months!

It shows little or no known side effects and has proven effective against the type of glaucoma that represents 75% of diagnosed cases.It's also an effective treatment for ocular hypertension, a condition that may lead to glaucoma.

Opportunity Snapshot


PNT has been shown to reduce or even eliminate the need for additional drug therapies.  Approximately 50% of responders have their drug therapy eliminated, with the remaining 50% can have their medication reduced.

What's Next?

After ten years research, development and testing and a $12-million investment, they're now ready to move towards full-scale, worldwide distribution.

That begins with explaining the procedure to the specialists who treat glaucoma and obtaining approvals from health care authorities around the world.



Their business plan for the period 2010-2014 projects total revenues for the five-year period of $240 million, with over $163-million in net earnings before taxes.  For accredited investors, this represents a very attractive
investment proposition that commends itself for immediate consideration.


They've already started the marketing process.  Distribution agreements are already in place for France, Italy, Spain, Portugal, Poland, Serbia, Canada, and China.  They're in negotiations for distribution to the remainder of the EU, Turkey, and Brazil.  To date, their distributors have invested over $63 million in international market development.